Jeremy Bender
Chief Executive Officer at DAY ONE BIOPHARMACEUTICALS, INC.
Net worth: 23 M $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Charles York | M | 47 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 3 years |
| Samuel Blackman | M | 55 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 6 years |
| Michael Gladstone | M | 37 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 5 years |
| Dan Becker | M | 49 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 5 years |
| Charles Sermon | M | 55 | 9 years | |
| Denise Scots-Knight | M | 64 | 9 years | |
| Sona Saira Ramasastry | F | 48 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 3 years |
| Michael Wyzga | M | 69 | 5 years | |
| Natalie Holles | F | 51 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 3 years |
| John Josey | M | 63 | 4 years | |
| Raphaël Rousseau | M | 55 | 1 years | |
| Garry Nicholson | M | 69 | 2 years | |
| Sandra Horning | M | 75 | 4 years | |
| Daniel O'Day | M | 59 | 5 years | |
| Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 years |
| John P. Richard | M | 66 | 9 years | |
| Edward Albini | M | 66 | 11 years | |
| Anders Olof Adolf Ekblom | M | 70 | 9 years | |
| Javier Rodriguez | M | 53 | 4 years | |
| John Freund | M | 70 | 10 years | |
| Harish M. Manwani | M | 70 | 6 years | |
| J. Garland | M | 55 | 3 years | |
| Deepa Pakianathan | M | 59 | 5 years | |
| Jaa Roberson | F | - | 3 years | |
| Suba Krishnan | M | 59 | 4 years | |
| Christine Fox | F | 43 | 3 years | |
| Pierre Jacquet | M | 57 | 3 years | |
| Lauren Merendino | F | 49 | 1 years | |
| Laura Cooper | F | - | 2 years | |
| Mike Pregih | M | - | - | |
| Joydeep Ganguly | M | - | 5 years | |
| Daniel Shames | M | 78 | 2 years | |
| Richard Francis | M | - | 5 years | |
| Janet Dorling | F | 50 | 4 years | |
| Johanna Mercier | F | 54 | 5 years | |
| Adam Dubow | M | 57 | 2 years | |
| Marc Yoskowitz | M | 49 | 2 years | |
| Justin Roberts | M | 42 | 2 years | |
| Habib Dable | M | 54 | - | |
| John Lewicki | M | 72 | 4 years | |
| William Grossman | M | 54 | - | |
| Wills Hughes-Wilson | F | 53 | 6 years | |
| Annalisa Jenkins | M | 58 | 2 years | |
| Merdad Parsey | M | 61 | 5 years | |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 years |
| Davy Chiodin | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregg Alton | M | 58 | 20 years | |
| Julie Grant | F | 41 | 5 years | |
| John Milligan | M | 63 | 28 years | |
| Stephen Hoffman | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 years |
| Pablo Cagnoni | M | 60 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
| Michael E. Hart | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 years |
| Alastair MacKinnon | M | 53 | 7 years | |
| John Valliant | M | 54 | 10 years | |
| Peter John Fellner | M | 80 | 7 years | |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
| Paul Blackburn | M | - | 5 years | |
| John McHutchison | M | 66 | 9 years | |
| Peter Bains | M | 65 | 6 years | |
| Anne Philomena Hyland | F | 64 | - | |
| Donald Bergstrom | M | 52 | 3 years | |
| Derek DiRocco | M | 43 | - | |
| Philina Lee | M | 47 | 3 years | |
| Shelly Pinto | F | 48 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | 5 years |
| Steven Gannon | M | 62 | 4 years | |
| Andrew Cheng | M | 57 | 19 years | |
| Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
| Robin Washington | F | 60 | 11 years | |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| John Martin | M | 72 | 29 years | |
| Barbara Duncan | F | 59 | 4 years | |
| Joseph Turner | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | - |
| Norbert W. Bischofberger | M | 68 | 28 years | |
| David Stout | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 years |
| Heather Elizabeth Preston | M | 58 | 4 years | |
| Chau Khuong | M | 48 | 4 years | |
| Kunal Ashok Kashyap | M | 59 | 6 years | |
| Johan Rutger Christenson | M | 65 | 6 years | |
| Aaron Brinkworth | M | - | 22 years | |
| Christopher Freeman | M | 50 | 1 years | |
| Lena Moran-Adams | F | - | 2 years | |
| Adrian Ray | M | 48 | 2 years | |
| Kate Butler | F | - | 3 years | |
| Monica Viziano | M | 57 | 18 years | |
| Martín Sebastian Olivo | M | 48 | 3 years | |
| Lian Hong Xu | M | 58 | 20 years | |
| Kitty Yale | F | 52 | 17 years | |
| Michael Quigley | M | 42 | 1 years | |
| Lee Song | F | 49 | 14 years | |
| John Sundy | M | 62 | 6 years | |
| Mark Genovese | M | - | 3 years | |
| Thomas Russo | M | 52 | 7 years | |
| Susannah Cantrell | M | - | 8 years | |
| Kenneth F. Boehm | M | - | 11 years | |
| Sung Lee | M | 53 | 14 years | |
| Martin J. Silverstein | M | 69 | 2 years | |
| David Gollaher | M | 74 | 4 years | |
| Minu Mittal | F | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 69 | 69.70% |
| United Kingdom | 22 | 22.22% |
| Canada | 9 | 9.09% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeremy Bender
- Personal Network
